TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TEMPLE CITY, Calif., Sept. 28, 2016 -- Fulgent Genetics announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $9.00 per share, before underwriting discounts and commissions. Fulgent Genetics has granted the underwriters a 30-day option to purchase up to an additional 630,000 shares from the company at the same price. The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the ticker symbol “FLGT.” The offering is expected to close on October 4, 2016, subject to customary closing conditions.
Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. are serving as joint book-running managers for the offering. Raymond James & Associates, Inc. is serving as lead manager and BTIG, LLC is serving as co-manager.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on September 28, 2016. The offering is being made solely by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, by telephone at +1-800-221-1037, or by email at [email protected]; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Suite 800, Minneapolis, MN 55402, by telephone at +1-800-747-3924, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
IR Contacts: Bob Jones 212-871-5570 [email protected] Chris Danne 415-217-5865 [email protected]
